Disc Medicine, Inc. (IRON) Stock Score, Valuation & Financial Research

Disc Medicine, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for IRON

Disc Medicine, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 65.46. These figures are a research snapshot, not a buy or sell recommendation.

What Disc Medicine, Inc. does

Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Disc Medicine is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research, development, and potential future commercialization of therapeutic candidates targeting hematologic diseases, funded primarily through equity financing and strategic collaborations.

Products and services

  • The company's pipeline includes bitopertin for erythropoietic porphyrias, DISC-0974 for anemia of myelofibrosis and inflammatory bowel disease, and DISC-3405 for polycythemia vera.

Customer types

Patients with hematologic diseases.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials; specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Pipeline of potentially first-in-class therapeutic candidates Source
  • Focus on fundamental biological pathways of red blood cell biology Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers for clinical supply Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

IRON financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 65.46
Market capitalization:
2.51B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -245.89M
Free cash flow:
USD -181.33M
Cash:
USD 98.68M
Total debt:
USD 60.86M
EPS:
USD -6.60

What stands out

  • Free cash flow is USD -181.33M, negative for the stored period.
  • The balance sheet shows USD 98.68M of cash versus USD 60.86M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 37.81M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for IRON

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can IRON fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is IRON likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for IRON to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of IRON's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research IRON

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.